Modelling and Optimal Control of Non-Viral siRNA Delivery

Jamili, Elnaz; Dua, Vivek

doi:10.1016/b978-0-444-63428-3.50117-x

Cited by 2 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A literature survey revealed that while a number of research works have been done on model‐based control of drug delivery (Dua, Dua, & Pistikopoulos, ), very little thought had been given to the development of control strategies for gene delivery systems (Dua, ; Jamili & Dua, ; Ma & Zhang, ). This paper presents the mathematical modeling, simulation and control of the dynamic process of non‐viral siRNA delivery.…”

Section: Introductionmentioning

confidence: 99%

“…However, no effort has been made to develop a holistic framework that is applicable for in vivo gene therapy, and provides a model-based decision-making platform taking into account the main multi-objective optimization issues, which consequently forms the main objective of this paper. A literature survey revealed that while a number of research works have been done on model-based control of drug delivery (Dua, Dua, & Pistikopoulos, 2010), very little thought had been given to the development of control strategies for gene delivery systems (Dua, 2012;Jamili & Dua, 2016;Ma & Zhang, 2009). This paper presents the mathematical modeling, simulation and control of the dynamic process of non-viral siRNA delivery.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Optimal model‐based control of non‐viral siRNA delivery

Jamili

Dua

2018

Biotech & Bioengineering

Self Cite

View full text Add to dashboard Cite

Further quantitative understanding of the biological effects and mechanisms involved in cellular and intracellular delivery of nucleic acid materials is required to produce clinical applications of gene therapy. Several modeling approaches have been used in this field; however, a comprehensive approach that integrates all the key pharmacological issues into a holistic framework that is applicable for in vivo conditions is still lacking. This contribution presents a pharmacokinetic/pharmacodynamic model-based control study of non-viral siRNA delivery describing the dynamics of the delivery process and takes into account the main multi-objective optimization issues such as efficacy and toxicity, as well as the effect of uncertainty in cell doubling time. The methodology developed in this work is used to predict the optimal dosage injection rate and optimal intracellular exposure of siRNAs in order to improve the pharmacological effects before cell division occurs. The present analysis successfully provides quantitative predictions of non-viral siRNA activity paving the path for further experimental work to probe more efficient delivery systems.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%